CSChristof Seifarth

Christof Seifarth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christof Seifarth has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and histological work-up of vitreoretinal metastases from cutaneous malignant melanoma

    by Antonia Osl, Georgios Blatsios, Teresa Rauchegger, Van Anh Nguyen, Christof Seifarth, Gertrud Haas

    We report a rare case of vitreoretinal metastases from cutaneous malignant melanoma (CMM). A 76-year-old patient with CMM presented at our clinic complaining of floaters and blurred vision in his right eye. After conducting an exploratory vitrectomy, the diagnosis of vitreoretinal metastases from CMM was made. Histopathology of the enucleated eye demonstrated residual clusters of malignant cells in the vitreous and focal invasion of the inner retina. CMM metastatic to the retina and vitreous is very rare. A detailed ophthalmological examination in all patients with metastatic CMM and complaints of ocular symptoms is highly recommended.

  • Open Access

    Effects of Intravitreal Aflibercept on the Systemic Insulin‐like Growth Factor‐I and Vascular Endothelial Growth Factor‐A in Patients with Diabetic Retinopathy and Age‐Related Macular Degeneration

    by Anna Lena Huber, Reinhard Angermann, Yvonne Nowosielski, Christof Seifarth, Martina T. Kralinger, Claus Zehetner

    Purpose . To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin‐like growth factor‐1 and vascular endothelial growth factor‐A in patients with diabetic retinopathy and age‐related macular degeneration. Methods . Vascular endothelial growth factor‐A and insulin‐like growth factor‐1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 μ l) for 19 patients with age‐related macular degeneration (mean age, 76 ± 11 years) and 18 patients with diabetic retinopathy (mean age, 64 ± 14 years). Twenty‐two healthy individuals were enrolled as controls. Results . A significant decline in systemic vascular endothelial growth factor‐A level, from 43 (30–57) pg/ml at baseline to 8 (8–8) pg/ml ( p < 0.001) at week one and 17 (8–25) pg/ml ( p = 0.0054) at week four, was observed in the age‐related macular degeneration group. In the diabetic retinopathy group, vascular endothelial growth factor‐A levels declined from 53 (35–117) pg/ml to 2 (1–5) pg/ml ( p < 0.0001) one week after injection and 16 (13–22) pg/ml four weeks after injection ( p = 0.0327). At baseline, systemic insulin‐like growth factor‐1 concentration was higher in the diabetic retinopathy group (57 [37–99] pg/ml) than in the age‐related macular degeneration group (35 [24–51] pg/ml) ( p = 0.0056). A subgroup analysis showed that patients in the proliferative diabetic retinopathy subgroup had significantly higher systemic insulin‐like growth factor‐1 concentrations (71 [44.7–243] pg/ml) than those in the nonproliferative diabetic retinopathy subgroup (43 [29–66] pg/ml) ( p = 0.0048). Conclusions . The difference between the baseline systemic insulin‐like growth factor‐1 levels of the age‐related macular degeneration and diabetic retinopathy groups and the higher insulin‐like growth factor‐1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin‐like growth factor‐1 may play a role in the pathomechanism of diabetic retinopathy.